Sven Francque, EASL ILC 2021: Subgroup Analysis of Semaglutide in NASH
It was a pleasure to speak with Prof. Dr Sven Francque (University of Antwerp, Belgium) about the recent post-hoc analysis of the phase 2 trial of semaglutide in patients with NASH. The analysis was designed to assess whether patient and disease characteristics influenced the effect of the drug on the resolution of NASH.
His abstract entitled ‘Semaglutide in patients with non-alcoholic steatohepatitis: subgroup analysis of a randomised, placebo-controlled phase 2 trial’ was presented at EASL ILC 2021, 23-26 June.
- What did the Phase 2 NN9931-4296 clinical trial teach us about the clinical utility of semaglutide in the treatment of patients with NASH? (0:10)
- Which subgroups were evaluated in the recent post-hoc analysis of the trial data? (0:54)
- What were the findings across the various subgroups, and what are the clinical implications of these findings? (1:30)
- Where do you think semaglutide will likely sit in the treatment paradigm for NASH? (2:12)
Disclosures: Prof. Dr Sven Francque has served as a speaker for AbbVie, Allergan, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Genentech, Genfit, Gilead, Intercept Pharmaceuticals, Inventiva, Novartis, NGM Bio, NovoNordisk and Roche. He has also acted as a consultant for AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Genentech, Genfit, Gilead, Intercept Pharmaceuticals, Inventiva, Novartis, NGM Bio, Novo Nordisk and Roche.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
Share this Video
Related Videos In Liver Disorders
Peter Ferenci, EASL ILC 2022: Wilson’s disease – diagnosis and treatment
Wilson’s disease is a rare, genetic disorder characterized by the accumulation of excess copper in vital organs such as the liver and brain. Damage caused by the excess copper build-up can lead to symptoms of liver and neurological diseases. In this touchENDOCRINOLOGY interview, we speak with Prof. Peter Ferenci (Medical University of Vienna, Vienna, Austria) […]
Camilla Dalby Hansen, EASL ILC 2022: Non-calorie restricted, low carbohydrate, high fat diet for NAFLD in T2DM
touchENDOCRINOLOGY spoke with Camilla Dably Hansen (Odense Hospital, Denmark) about the findings from the recent 6-month randomised controlled trial investigating the impact of a non-calorie restricted, low carbohydrate, high fat diet on nonalcoholic fatty liver disease (NAFLD) activity score (NAS) and HbA1c in patients with type 2 diabetes (T2DM). The abstract entitled ‘A non-calorie restricted […]
Aleksander Krag, EASL 2022: International Liver Congress Update
We caught up with the European Association for the Study of the Liver (EASL) Vice-Secretary, Prof. Aleksander Krag, to discuss the upcoming International Liver Congress (ILC) and what to expect. At ILC 2022 they will be bringing back face-to-face meetings in a new model, reshaping the scientific programme, offering a fresh experience, merging the very best […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!